Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Changeyoubet
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(571)
•••
Comment by IrishCanuckon Jun 29, 2021 1:13pm
173 Views
Post# 33466625

RE:RE:RE:RE:Changeyoubet

RE:RE:RE:RE:Changeyoubet

Is anyone here not from Ontario? Even in Canada but in Ontario you should be acutely aware how locked down our province has been since before Christmas... you know... with additional lockdowns since the Jan. 11 update.

You think ATE was allowed to conduct their AME studies while the administrators were worried about COVID overwhelming hospital capacity? Cancer patients couldn't even get surgery they just jad to wait. And now we're entering another stage of reopening as AME is allowed to begin... then we'll know the dose for Phase 3 as the whole point of AME is to de-risk dose selection... which is why AME is 6 weeks to reach maximum NSAID levels in the body and be the lowest effective dose which FDA wants...

There's no magic ultra level Illumanati conspiracy folks pretty easy to see where the hiccups are

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities